AirSeq: How Airborne DNA Sequencing Is Revolutionizing Pathogen Detection

A new joint venture between the Natural History Museum and Earlham Institute launches AirSeq technology, enabling rapid, unbiased detection of airborne pathogens through DNA sequencing.

A New Era in Airborne Threat Detection

Imagine walking into a hospital, a greenhouse, or a food processing facility and knowing within hours exactly which microscopic organisms are floating in the air—bacteria, viruses, fungi, pollen, and more. This capability is no longer science fiction. A groundbreaking technology called AirSeq, developed through a partnership between London’s Natural History Museum and the Norwich-based Earlham Institute, is making comprehensive airborne DNA analysis a commercial reality.,The technology has been spun out into a new company, Agnos Biosciences, marking the first venture of its kind in the Natural History Museum’s history. By combining novel molecular biology methods with advanced computational analysis, AirSeq offers what traditional monitoring systems cannot: an unbiased, non-targeted approach that can identify thousands of species simultaneously from a single air sample.

How AirSeq Technology Works

At its core, AirSeq is an end-to-end service that transforms air into actionable biological data. The process begins with specialized air sampling devices that capture airborne particles onto filters or into liquid media. These samples then undergo DNA extraction in a laboratory setting, followed by high-throughput sequencing.,What distinguishes AirSeq from conventional pathogen detection methods is its computational backbone. The platform employs bespoke bioinformatics pipelines that can analyze complex metagenomic data—genetic material recovered directly from environmental samples—to identify and quantify the full spectrum of biological material present. Unlike targeted PCR tests that look for specific known pathogens, AirSeq sequences everything, revealing both expected and unexpected organisms.,The system’s low false positive rate is particularly noteworthy. In fields where false alarms can trigger costly shutdowns or unnecessary panic, this reliability makes AirSeq suitable for high-stakes environments ranging from pharmaceutical clean rooms to biodefense applications.

From Research Lab to Real-World Applications

AirSeq didn’t emerge overnight. The technology represents years of research and development funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and other public and philanthropic funding bodies in both the UK and US. A significant validation came through extensive research with the United States’ Defense Advanced Research Projects Agency (DARPA), where the technology demonstrated its capabilities for biological threat detection.,Today, AirSeq is already serving customers across multiple sectors in the UK. In agriculture, it enables early detection of crop pathogens before visible symptoms appear, allowing for targeted interventions that reduce pesticide use and crop losses. Food manufacturers use it to monitor production environments for contamination risks. Environmental scientists deploy it for biodiversity assessments and ecosystem health monitoring. Each application benefits from the same core advantage: comprehensive, unbiased data delivered rapidly enough to inform decisions.

The Dual-Use Nature of Environmental Genomics

Agnos Biosciences describes itself as a dual-use venture, serving both civilian and defense applications. This reflects a growing recognition that the fundamental challenge—detecting biological agents in air—is shared across domains. A hospital monitoring for airborne infections, a farm watching for crop diseases, and a security agency screening for biological threats all need the same underlying capability: rapid, accurate identification of airborne DNA.,The company’s leadership brings together deep scientific expertise with commercial acumen. Professor Matt Clark, Research Leader at the Natural History Museum, serves as Chief Scientific Officer. Dr. Richard Leggett, Group Leader at the Earlham Institute, holds the Chief Technology Officer role. Simon Kim, the Museum’s Entrepreneur in Residence, leads as CEO. This structure ensures that cutting-edge research translates directly into practical services.

Institutional Innovation in the Cultural Sector

The formation of Agnos Biosciences represents a broader shift in how research-intensive cultural institutions operate. The Natural History Museum’s Strategy and Innovation Unit, created in 2023, aims to translate the work of its 400 scientists into scalable impact. As Director of Strategy and Innovation Bethan Parry notes, the goal is to deploy museum research for planetary, societal, and economic benefit.,For the Earlham Institute, this marks their second spinout company. Head of Business Development and Impact Dr. Liliya Serazetdinova emphasizes the institute’s commitment to translating genomics research into real-world applications. The Norwich Research Park location, home to eight institutes receiving strategic BBSRC funding, provides a collaborative ecosystem that accelerates such translation.

Future Horizons: Clean Rooms, Biopharma, and Beyond

The potential applications for AirSeq continue to expand. In pharmaceutical manufacturing, where sterile conditions are paramount, continuous airborne monitoring could detect contamination events before they compromise entire batches. The technology’s developers even envision applications in space exploration, where monitoring microbial communities in closed habitats is critical for astronaut health.,In biopharmaceutical development, understanding the airborne microbiome of research and production facilities could improve quality control and regulatory compliance. As genomic sequencing costs continue to fall and computational methods grow more sophisticated, the barriers to widespread adoption of environmental DNA monitoring are rapidly diminishing.

Conclusion

AirSeq represents a significant leap forward in our ability to understand and respond to the invisible biological world around us. By making comprehensive airborne DNA analysis fast, accurate, and commercially accessible, Agnos Biosciences is bridging the gap between cutting-edge genomics research and practical biosecurity needs. The technology’s unbiased nature—detecting what we don’t know to look for as well as what we do—may prove its most valuable feature in an era where emerging pathogens and environmental change demand vigilant, adaptable monitoring systems. As this Museum-born innovation moves into wider deployment, it offers a compelling model for how cultural and scientific institutions can translate fundamental research into tools that protect public health, food security, and ecological resilience.

---

Image Credit:

Nicola Narracci